These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 25790347)

  • 1. Successful topical rapamycin treatment for facial angiofibromata in two children.
    Pynn EV; Collins J; Hunasehally PR; Hughes J
    Pediatr Dermatol; 2015; 32(3):e120-3. PubMed ID: 25790347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin.
    Kaufman McNamara E; Curtis AR; Fleischer AB
    J Dermatolog Treat; 2012 Feb; 23(1):46-8. PubMed ID: 20673154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Facial angiofibromas associated to tuberous sclerosis treated with topical sirolimus].
    Tiedemann Svendsen M; Bygum A; Hansen LK; Broesby-Olsen S
    Ugeskr Laeger; 2013 Oct; 175(43):2569-70. PubMed ID: 24629155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical 0.2% rapamycin to treat facial angiofibromas and hypomelanotic macules in tuberous sclerosis.
    Knöpfel N; Martín-Santiago A; Bauza A; Hervás JA
    Actas Dermosifiliogr; 2014 Oct; 105(8):802-3. PubMed ID: 24355193
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1) ) in two patients with tuberous sclerosis.
    Mutizwa MM; Berk DR; Anadkat MJ
    Br J Dermatol; 2011 Oct; 165(4):922-3. PubMed ID: 21692776
    [No Abstract]   [Full Text] [Related]  

  • 6. A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex.
    Wheless JW; Almoazen H
    J Child Neurol; 2013 Jul; 28(7):933-6. PubMed ID: 23680945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Topical sirolimus 0.4% formulation for treatment of facial angiofibromas].
    Cuevas Asencio I; Albornoz López R; Salido Vallejo R; Reyes Malia M
    Farm Hosp; 2012; 36(5):433-4. PubMed ID: 22858090
    [No Abstract]   [Full Text] [Related]  

  • 8. First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex.
    Tanaka M; Wataya-Kaneda M; Nakamura A; Matsumoto S; Katayama I
    Br J Dermatol; 2013 Dec; 169(6):1314-8. PubMed ID: 23909960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex : A Randomized Clinical Trial.
    Wataya-Kaneda M; Nakamura A; Tanaka M; Hayashi M; Matsumoto S; Yamamoto K; Katayama I
    JAMA Dermatol; 2017 Jan; 153(1):39-48. PubMed ID: 27837201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients.
    Foster RS; Bint LJ; Halbert AR
    Australas J Dermatol; 2012 Feb; 53(1):52-6. PubMed ID: 22309333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Facial angiofibromas treated with topical rapamycin: an excellent choice with fast response.
    Truchuelo T; Díaz-Ley B; Ríos L; Alcántara J; Jaén P
    Dermatol Online J; 2012 Jan; 18(1):15. PubMed ID: 22301052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex.
    Balestri R; Neri I; Patrizi A; Angileri L; Ricci L; Magnano M
    J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):14-20. PubMed ID: 25174683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis.
    Hofbauer GF; Marcollo-Pini A; Corsenca A; Kistler AD; French LE; Wüthrich RP; Serra AL
    Br J Dermatol; 2008 Aug; 159(2):473-5. PubMed ID: 18547304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: follow up of a pilot study and promising future directions.
    Tu J; Foster RS; Bint LJ; Halbert AR
    Australas J Dermatol; 2014 Feb; 55(1):63-9. PubMed ID: 24359523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis.
    Haemel AK; O'Brian AL; Teng JM
    Arch Dermatol; 2010 Jul; 146(7):715-8. PubMed ID: 20644030
    [No Abstract]   [Full Text] [Related]  

  • 16. [Topical rapamycin solution to treat multiple facial angiofibromas in a patient with tuberous sclerosis].
    Valerón-Almazán P; Vitiello M; Abuchar A; Kerdel FA
    Actas Dermosifiliogr; 2012 Mar; 103(2):165-6. PubMed ID: 21861956
    [No Abstract]   [Full Text] [Related]  

  • 17. Acneiform Lesion: Importance of Detailed Skin Examination.
    Samanta D
    Indian J Pediatr; 2016 May; 83(5):485-6. PubMed ID: 26558921
    [No Abstract]   [Full Text] [Related]  

  • 18. [Successful treatment of facial angiofibromas with local sirolimus in childhood in Bourneville-Pringle disease].
    Bottyán K; Kemény L; Csoma ZR
    Orv Hetil; 2019 Mar; 160(13):516-520. PubMed ID: 30907099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted topical and combination laser surgery for the treatment of angiofibromas.
    Bae-Harboe YS; Geronemus RG
    Lasers Surg Med; 2013 Nov; 45(9):555-7. PubMed ID: 24136238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol.
    DeKlotz CM; Ogram AE; Singh S; Dronavalli S; MacGregor JL
    Arch Dermatol; 2011 Sep; 147(9):1116-7. PubMed ID: 21931059
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.